• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

The 7 Pillars of Healthcare Strength

Here are healthcare stocks of all shares and sizes with strong charts.
By JIM CRAMER
Mar 23, 2015 | 06:00 AM EDT
Stocks quotes in this article: BIIB, OC, ASH, AMGN, BMRN, CELG, REGN, VRTX, ALXN, PCYC, ISIS, BMY, LLY, ABC, MCK, CAH, AET, ANTM, CI, HUM, UNH, ACT, BDX, MDT, MNK, TMO, HSIC, SRCL, DGX, PRGO, TEVA, MYL, CERN, WBA, CVS, RAD

You know how you could have -- and may still -- handily beat the averages?

Simply develop a portfolio of healthcare companies of all shapes and sizes that do nothing but try to service the colossus that is the American medical system.

As I peruse the charts this weekend, it almost seems too easy. There's simply nothing like this group. Oh sure, there are the companies that do well in a low-energy regime: hotels, restaurants, retailers, truckers and even the derivative plays like Owens Corning (OC) and Ashland (ASH). These are stocks that everyone knows except those who still believe that the additional dollars aren't being spent. That non-spend thesis has kept you out of the second-best group of stocks for certain.

But it is pretty unbelievable how much money has poured into the healthcare sector.

We all know this is the era when Amgen (AMGN), BioMarin (BMRN), Biogen-Ideec (BIIB), Celgene (CELG), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Pharmacyclics (PCYC), Isis Pharma (ISIS) and so many other biotechs became the darlings of a lower-growth lower-interest-rate environment. A combination of voracious large capitalization drug stocks not having a real pipeline to keep up with their generic cliffs and the creation of blockbuster drugs from years of research has propelled this group.

(Check out Trifecta Stocks' Bob Lang's latest technical analysis of CEL, ISIS and CVS and chart work of Real Money Pro's Gary Berman's on AGMN. Also, Real Money Pros's Rob Moreno IDs two biotech that may be ripe for a short.)

Amgen (AMGN)
Source: FreeStockCharts.com
View Chart » View in New Window »
BioMarin Pharman (BMRN)
Source: FreeStockCharts.com
View Chart » View in New Window »
Biogen-Idec (BIIB)
Source: FreeStockCharts.com
View Chart » View in New Window »
Celgene (CELG)
Source: FreeStockCharts.com
View Chart » View in New Window »
Regeneron (REGN)
Source: FreeStockCharts.com
View Chart » View in New Window »
Vertex (VRTX)
Source: FreeStockCharts.com
View Chart » View in New Window »
Alexion (ALXN)
Source: FreeStockCharts.com
View Chart » View in New Window »
Pharmacyclics (PCYC)
Source: FreeStockCharts.com
View Chart » View in New Window »
ISIS Pharma (ISIS)
Source: FreeStockCharts.com
View Chart » View in New Window »

The only outliers in old pharma, at least when it comes to the charts, are Bristol-Myers (BMY) and Lilly (LLY), the former a re-rating of an old line drug company to a fast-growing one and the latter just a plain out-and-out mystery to me, an overvalued stock that never comes in.

Bristol-Myers (BMY)
Source: FreeStockCharts.com
View Chart » View in New Window »
Eli Lilly (LLY)
Source: FreeStockCharts.com
View Chart » View in New Window »

Beyond biotechs, the second group that astounds remains the companies that rein in costs to the system: AmerisourceBergen (ABC), McKesson (MCK) and Cardinal Health (CAH) continue to dominate. These stocks never quit and the analysts' love for them never stops. These are perhaps the most amazing stocks of the era because what they do is so obvious and they do it so consistently that it's almost like these stocks were created for stock market performance.

AmerisourceBergen (ABC)
Source: FreeStockCharts.com
View Chart » View in New Window »
McKesson (MCK)
Source: FreeStockCharts.com
View Chart » View in New Window »
Cardinal Health (CAH)
Source: FreeStockCharts.com
View Chart » View in New Window »

The third group health group that never seems to stop delivering, despite endless attempts by analysts to call the top? The health maintenance organizations that turned out to be the biggest winners of the Affordable Care Act: Aetna (AET), Anthem (ANTM), Cigna (CI), Humana (HUM) and UnitedHealth (UNH). I don't even know if it is worth distinguishing them anymore. I have had such a hard time with these because I have repeatedly thought they were done or had to have run out of gas. The charitable trust got a fantastic move out of Cigna and it turned out we got a small fraction of what this company's stock has given you.

Aetna (AET)
Source: FreeStockCharts.com
View Chart » View in New Window »
Anthem (ANTM)
Source: FreeStockCharts.com
View Chart » View in New Window »
Cigna (CI)
Source: FreeStockCharts.com
View Chart » View in New Window »
Humana (HUM)
Source: FreeStockCharts.com
View Chart » View in New Window »
UnitedHealth (UNH)
Source: FreeStockCharts.com
View Chart » View in New Window »

As we are basically in inning two of the Affordable Care Act and it is now unlikely to be rolled back, it is reasonable to think that these stocks aren't even done going higher, especially when you consider that Aetna and Cigna trade at discounts to the S&P 500 at 15x earnings! Don't forget these are also levered to increased employment in the country. So they are doubly blessed.

The fourth group? Those that have augmented their fortunes through mergers: Actavis (ACT), Becton Dickinson (BDX), Medtronic (MDT), Mallinckrodt (MNK), and Thermo Fisher (TMO). These companies have many years of earnings growth ahead either because of they are now inverted (Actavis and Medtronic) or because their acquisitions have so much synergy. These stocks are miracles, frankly, with Actavis being the best example. I have spent some time with CEO Brent Saunders and was initially a tad skeptical because I have not particularly liked what look like roll-ups. But calling Actavis a roll-up seems almost insulting now.

Actavis (ACT)
Source: FreeStockCharts.com
View Chart » View in New Window »
Becton Dickinson (BDX)
Source: FreeStockCharts.com
View Chart » View in New Window »
Medtronic (MDT)
Source: FreeStockCharts.com
View Chart » View in New Window »
Mallinckrodt (MNK)
Source: FreeStockCharts.com
View Chart » View in New Window »
Thermo Fisher (TMO)
Source: FreeStockCharts.com
View Chart » View in New Window »

The fifth group: the suppliers and ancillary service companies. Here I prefer Henry Schein (HSIC), just added to the S&P 500, Laboratory (LH), Stericycle (SRCL) and Quest Diagnostics (DGX). These stocks seem to have no roof on them whatsoever. The stock market always loves this kind of company because we are always doing more testing and more examining and that makes these stocks ideal.

Henry Schein (HSIC)
Source: FreeStockCharts.com
View Chart » View in New Window »
Laboratory (LH)
Source: FreeStockCharts.com
View Chart » View in New Window »
Stericycle (SRCL)
Source: FreeStockCharts.com
View Chart » View in New Window »
Quest Diagnostics (DGX)
Source: FreeStockCharts.com
View Chart » View in New Window »

Sixth, there are the companies that are perceived as saving the system money: Perrigo (PRGO), Teva (TEVA), Mylan (MYL) and Cerner (CERN). The first three are generic drug companies that have been on fire of late and the third is the consistent supplier of healthcare solutions. Perrigo has always been my favorite because of its unique combination of knock-offs and prescription drugs. I have traditionally not liked Teva or Mylan because they, chiefly, are commodity players. But I now feel that I have become too much of a snob as this rising tide is lifting all boats.

Perrigo (PRGO)
Source: FreeStockCharts.com
View Chart » View in New Window »
Teva (TEVA)
Source: FreeStockCharts.com
View Chart » View in New Window »
Mylan (MYL)
Source: FreeStockCharts.com
View Chart » View in New Window »

Finally, seventh, there are the drugstore chains, Walgreens Boots Alliance (WBA), CVS Health (CVS) and Rite Aid (RAD). The first is at the beginning of internationalization, the second is the pioneer of new paradigm (a retail healthcare company) and the latter is attempting to be the next CVS with its recent acquisition of a pharmacy benefit manager.

Walgreen Boots Alliance (WBA)
Source: FreeStockCharts.com
View Chart » View in New Window »
CVS Health (CVS)
Source: FreeStockCharts.com
View Chart » View in New Window »
Rite Aid (RAD)
Source: FreeStockCharts.com
View Chart » View in New Window »

Now, of course, I have left out a ton of stocks in this survey course of the group. And I have chosen to highlight only the ones that hit me by looking at the best charts over the weekend. But you need to focus on this list because if we are going to have a selloff related to a slowdown of some sort the buyers will come right back to this group and its seven pillars of strength.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long TMO and WBA.

TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

2 More Covered Call Opportunities That Are Calling Investors

Bret Jensen
Jan 25, 2021 8:30 AM EST

Here are options plays involving promising small-caps Clearside Biomedical and Mustang Bio.

Trade Carefully With Soaring Gritstone Oncology

Bruce Kamich
Jan 21, 2021 8:16 AM EST

The history we are concerned about is the past couple of weeks.

UnitedHealth Group Charts Appear Toppy Ahead of Earnings

Bruce Kamich
Jan 19, 2021 8:53 AM EST

The technical indicators of the health benefits concern are not sending strong signals at present.

Moderna Now Looks Like an Effective Long Trade With Few Side Effects

Bruce Kamich
Jan 14, 2021 12:06 PM EST

MRNA has corrected its big November rally and now looks ready to start a fresh advance, according to the charts.

Pacific Biosciences Reaches Our Price Target: Now What?

Bruce Kamich
Jan 13, 2021 12:19 PM EST

Let's check out the charts and technical indicators.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:35 AM EST CHRIS VERSACE

    Another Big Winner for Stocks Under $10

    We're ringing the register Tuesday morning.
  • 08:05 AM EST GARY BERMAN

    Tuesday Morning Fibocall for 1/26/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 09:52 AM EST GARY BERMAN

    INDU/DIA 20 DMA

    Fibocall: The DIA has the 20 DMA @ 307.81 and w...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login